206 related articles for article (PubMed ID: 12010138)
1. Neoral rescue therapy in transplant patients with intolerance to tacrolimus.
Abouljoud MS; Kumar MS; Brayman KL; Emre S; Bynon JS;
Clin Transplant; 2002 Jun; 16(3):168-72. PubMed ID: 12010138
[TBL] [Abstract][Full Text] [Related]
2. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
3. Conversion from tacrolimus to cyclosporine microemulsion therapy in liver transplant recipients.
Ogino S; Hashikura Y; Katsuyama Y; Ikegami T; Nakazawa Y; Urata K; Terada M; Miyagawa S; Kawasaki S
Transplant Proc; 2004 Mar; 36(2 Suppl):299S-301S. PubMed ID: 15041357
[TBL] [Abstract][Full Text] [Related]
4. New strategies using 'low-dose' mycophenolate mofetil to reduce acute rejection in patients following kidney transplantation.
Ulsh PJ; Yang HC; Holman MJ; Ahsan N
J Transpl Coord; 1999 Jun; 9(2):114-8. PubMed ID: 10703393
[TBL] [Abstract][Full Text] [Related]
5. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
6. Conversion to cyclosporine provides valuable rescue therapy for living donor adult liver transplant patients intolerant to tacrolimus: A single-center experience at the University of Tokyo.
Tamura S; Sugawara Y; Kishi Y; Akamatsu N; Kaneko J; Murai N; Makuuchi M
Transplant Proc; 2004 Dec; 36(10):3242-4. PubMed ID: 15686738
[TBL] [Abstract][Full Text] [Related]
7. Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia: the Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsion.
White M; Haddad H; Leblanc MH; Giannetti N; Pflugfelder P; Davies R; Isaac D; Burton J; Chan M; Azevedo E; Howlett J; Ignaszewski A; Busque S; Cantarovich M; Ferguson R; Genest J; Ross H
J Heart Lung Transplant; 2005 Jul; 24(7):798-809. PubMed ID: 15982605
[TBL] [Abstract][Full Text] [Related]
8. Calcineurin inhibitors in pediatric renal transplant recipients.
Filler G
Paediatr Drugs; 2007; 9(3):165-74. PubMed ID: 17523697
[TBL] [Abstract][Full Text] [Related]
9. Calcineurin inhibitors in renal transplantation: what is the best option?
Tanabe K
Drugs; 2003; 63(15):1535-48. PubMed ID: 12887261
[TBL] [Abstract][Full Text] [Related]
10. Calcineurin inhibitors in heart transplantation.
Keogh A
J Heart Lung Transplant; 2004 May; 23(5 Suppl):S202-6. PubMed ID: 15093806
[TBL] [Abstract][Full Text] [Related]
11. Increased early rejection rate after conversion from tacrolimus in kidney and pancreas transplantation.
Barone GW; Ketel BL; Abul-Ezz SR; Lightfoot ML
JOP; 2002 Mar; 3(2):49-53. PubMed ID: 11884766
[TBL] [Abstract][Full Text] [Related]
12. Tacrolimus: a further update of its use in the management of organ transplantation.
Scott LJ; McKeage K; Keam SJ; Plosker GL
Drugs; 2003; 63(12):1247-97. PubMed ID: 12790696
[TBL] [Abstract][Full Text] [Related]
13. Tacrolimus rescue in liver transplant patients with refractory rejection or intolerance or malabsorption of cyclosporine. The US Multicenter FK506 Liver Study Group.
Klein A
Liver Transpl Surg; 1999 Nov; 5(6):502-8. PubMed ID: 10545538
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
[TBL] [Abstract][Full Text] [Related]
15. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation.
Dunn CJ; Wagstaff AJ; Perry CM; Plosker GL; Goa KL
Drugs; 2001; 61(13):1957-2016. PubMed ID: 11708766
[TBL] [Abstract][Full Text] [Related]
16. Conversion to neoral for neurotoxicity after primary adult liver transplantation under tacrolimus.
Jain A; Brody D; Hamad I; Rishi N; Kanal E; Fung J
Transplantation; 2000 Jan; 69(1):172-6. PubMed ID: 10653398
[TBL] [Abstract][Full Text] [Related]
17. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine.
Armstrong VW; Oellerich M
Clin Biochem; 2001 Feb; 34(1):9-16. PubMed ID: 11239509
[TBL] [Abstract][Full Text] [Related]
18. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria.
Morrissey PE; Gohh R; Shaffer D; Crosson A; Madras PN; Sahyoun AI; Monaco AP
Transplantation; 1997 Mar; 63(6):845-8. PubMed ID: 9089224
[TBL] [Abstract][Full Text] [Related]
19. Conversion from cyclosporine to tacrolimus in pediatric kidney transplant recipients.
Ferraresso M; Ghio L; Edefonti A; Garavaglia R; Berardinelli L
Pediatr Nephrol; 2002 Aug; 17(8):664-7. PubMed ID: 12185478
[TBL] [Abstract][Full Text] [Related]
20. Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients.
Emre S; Genyk Y; Schluger LK; Fishbein TM; Guy SR; Sheiner PA; Schwartz ME; Miller CM
Transpl Int; 2000; 13(1):73-8. PubMed ID: 10743694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
